REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System

Transcatheter Aortic Valve Replacement Clinical Trial

Official title:

REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Evaluation of Safety and Performance

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01627691
• Other study ID #: TP3687
• Secondary ID: TP3687
• Status: Completed
• Phase: N/A
• Start date: October 8, 2012
• Est. completion date: May 13, 2019

Study information

• Verified date: April 2020
• Source: Boston Scientific Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and performance of the Lotus™ Valve System for transcatheter aortic valve replacement (TAVR) in symptomatic subjects with severe calcific aortic stenosis who are considered high risk for surgical valve replacement.

Description:

The REPRISE II clinical study is a prospective, single-arm, multicenter study designed to evaluate the safety and performance of the Lotus Valve System for TAVR in symptomatic subjects who have severe calcific aortic valve stenosis and who are at high risk for surgical aortic valve replacement (SAVR).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 250
• Est. completion date: May 13, 2019
• Est. primary completion date: May 30, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 70 Years and older

Eligibility

Inclusion Criteria:

• Subject is =70 years of age

• Subject has documented calcific native aortic valve stenosis

• Subject has a documented aortic annulus size between =19 and =27 mm based on pre-procedure diagnostic imaging

• Symptomatic aortic valve stenosis with NYHA Functional Class = II

• Subject is considered high risk for surgical valve replacement

• Heart team assessment that the subject is likely to benefit from valve replacement.

• Subject (or legal representative) understands the study requirements and the treatment procedures, and provides written informed consent.

• Subject, family member, and/or legal representative agree(s) and subject is capable of returning to the study hospital for all required scheduled follow up visits.

Exclusion Criteria:

• Subject has a congenital unicuspid or bicuspid aortic valve.

• Subject with an acute myocardial infarction within 30 days of the index procedure

• Subject has had a cerebrovascular accident or transient ischemic attack within the past 6 months, or has any permanent neurologic defect prior to study enrollment.

• Subject is on dialysis or has serum creatinine level >3.0 mg/dL or 265 µmol/L.

• Subject has a pre-existing prosthetic heart valve (aortic or mitral) or a prosthetic ring in any position.

• subject cannot have more than moderate mitral, aortic or tricuspid regurgitation

• Subject has a need for emergency surgery for any reason.

• Subject has a history of endocarditis within 12 months of index procedure or evidence of an active systemic infection or sepsis.

• Subject has echocardiographic evidence of intra-cardiac mass, thrombus or vegetation.

• Subject has low Hgb, platelet count or >700,000 cells/mm3, or low white blood cell count.

• Subject requires chronic anticoagulation therapy and cannot tolerate concomitant therapy with either aspirin or clopidogrel/ticlopidine

• Subject has active peptic ulcer disease or gastrointestinal bleed within the past 3 months, other bleeding diathesis or coagulopathy or will refuse transfusions.

• Subject has known hypersensitivity to contrast agents that cannot be adequately pre-medicated, or has known hypersensitivity to aspirin, all thienopyridines, heparin, nickel, tantalum, titanium, or polyurethanes.

• Subject has a life expectancy of less than 12 months due to non-cardiac, co-morbid conditions based on the assessment of the investigator at the time of enrollment.

• Subject has hypertrophic obstructive cardiomyopathy.

• Subject has any therapeutic invasive cardiac procedure within 30 days prior to the index procedure (except for pacemaker implantation which is allowed).

• Subject has untreated coronary artery disease.

• Subject has documented left ventricular ejection fraction <30%.

• Subject is in cardiogenic shock or has hemodynamic instability requiring inotropic support or mechanical support devices.

• Subject has severe peripheral vascular disease or symptomatic carotid or vertebral disease.

• Narrow Femoral artery lumen precludes the use of either Lotus device size, or severe iliofemoral tortuosity or calcification that would prevent safe placement of the introducer sheath.

• Current problems with substance abuse (e.g., alcohol, etc.).

• Subject is participating in another investigational drug or device study that has not reached its primary endpoint.

• Patient has preexisting untreated conduction system disorder that requires new pacemaker implantation.

Related Conditions & MeSH terms

• Transcatheter Aortic Valve Replacement

Intervention

Device:
• Lotus Valve System
bioprosthetic bovine pericardial aortic valve delivery system

Locations

Country	Name	City	State
Australia	Royal Adelaide Hospital	Adelaide
Australia	Prince Charles Hospital	Brisbane
Australia	Monash Medical Center	Melbourne
Australia	St. Vincent's Hospital	Melbourne
France	Hôpital Cardiologique CHRU de Lille	Lille
France	Hôpital Cardiologique de Lyon	Lyon
France	Institut Cardiovasculaire Paris Sud	Paris
France	Centre Hôpital Universitaire Rangueil	Toulouse
France	Clinique Pasteur	Toulouse
Germany	Deutsches Herzzentrum München	München
Germany	Helios Klinikum Siegburg	Siegburg
Italy	Ospedale Ferrarotto	Catania
Netherlands	Erasmus MC - Thorax Center	Rotterdam
Spain	Hospital Clinico San Carlos	Madrid
Sweden	University Hospital of Lund	Lund
Switzerland	INSELSPITAL - Universitätsspital Bern	Bern
United Kingdom	Royal Victoria Hospital	Belfast
United Kingdom	Royal Sussex County Hospital	Brighton
United Kingdom	The General Infirmary	Leeds
United Kingdom	Guys and St. Thomas NHS Foundation Trust	London

Sponsors (1)

Lead Sponsor	Collaborator
Boston Scientific Corporation

Countries where clinical trial is conducted

Australia,  France,  Germany,  Italy,  Netherlands,  Spain,  Sweden,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Device Performance Endpoint: Mean Aortic Valve Pressure Gradient at 30 Days Post Implant Procedure	Mean aortic valve pressure gradient at 30 days post implant procedure as measured by echocardiography and assessed by an independent core laboratory.	30 days
Primary	Primary Safety Endpoint: All-cause Mortality at 30 Days Post Implant Procedure	Mortality at 30 days from all patients enrolled in the study (ITT population): the proportion of patients who experience an event through 30 days post-procedure out of the patients who have either had an event within 30 days post-procedure or who were event-free with last follow-up at least 23 days post-procedure	30 days
Secondary	Effective Orifice Area	Effective orifice area measured by echocardiography at 30 days and assessed by an independent core laboratory (ITT population)	30 days
Secondary	Device Performance Endpoint: Successful Vascular Access	Successful vascular access, delivery and deployment of the Lotus Valve System and successful retrieval of the delivery system as reported from site	Post-procedure
Secondary	Device Performance Endpoint: Successful Retrieval	Successful retrieval (complete resheathing of the Lotus valve in the catheter and removal from the body) of the Lotus Valve System if retrieval is attempted, as reported from site	Post-procedure
Secondary	Device Performance Endpoint: Successful Repositioning	Successful repositioning (partial or complete resheathing of the Lotus Valve in the catheter and redeployment in a more accurate position within the aortic valve annulus) of the Lotus Valve System if repositioning is attempted for the last valve attempted, as reported from site	Post-procedure
Secondary	Device Success According to the Valve Academic Research Consortium (VARC)	Absence of procedural mortality as reported from site AND Correct positioning of a single prosthetic heart valve into the proper anatomical location as reported from site AND Intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient <20 mmHg or peak velocity <3 m/s, AND no moderate or severe prosthetic valve regurgitation as measured from an independent core lab on the post-procedure echocardiography)	Post-procedure
Secondary	Grade of Aortic Valve Regurgitation	Grade of paravalvular aortic valve regurgitation at 30 days as measured by echocardiography and assessed by an independent core laboratory	30 days